Filing Details
- Accession Number:
- 0000950170-24-072122
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-11 19:01:55
- Reporting Period:
- 2024-06-11
- Accepted Time:
- 2024-06-11 19:01:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1682852 | Moderna Inc. | MRNA | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1222012 | Noubar Afeyan | C/O Flagship Pioneering, Inc. 55 Cambridge Parkway, Suite 800E Cambridge MA 02142 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-06-11 | 163,649 | $148.29 | 7,937,145 | No | 4 | S | Indirect | By Flagship Ventures Fund IV, L.P. |
Common Stock | Disposition | 2024-06-11 | 31,531 | $148.29 | 1,529,789 | No | 4 | S | Indirect | By Flagship Ventures Fund IV-Rx, L.P. |
Common Stock | Disposition | 2024-06-11 | 6,420 | $149.40 | 7,930,725 | No | 4 | S | Indirect | By Flagship Ventures Fund IV, L.P. |
Common Stock | Disposition | 2024-06-11 | 1,232 | $149.40 | 1,528,557 | No | 4 | S | Indirect | By Flagship Ventures Fund IV-Rx, L.P. |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By Flagship Ventures Fund IV, L.P. |
No | 4 | S | Indirect | By Flagship Ventures Fund IV-Rx, L.P. |
No | 4 | S | Indirect | By Flagship Ventures Fund IV, L.P. |
No | 4 | S | Indirect | By Flagship Ventures Fund IV-Rx, L.P. |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 3,924 | Indirect | By Flagship Pioneering, Inc. |
Common Stock | 1,946,931 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.00 to $148.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- The shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.00 to $149.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.